Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab

被引：0

作者：

Sun, Jingshu ^{[1
]}

Wu, Shengqin ^{[1
]}

Yin, Fang ^{[1
]}

Zhang, Kunying ^{[1
]}

Wang, Jianying ^{[1
]}

机构：

[1] Weifang Peoples Hosp, Weifang 151 Guangwen St, Kuiwen 261000, Peoples R China

来源：

CLINICAL NEPHROLOGY | 2024年 / 103卷 / 01期

关键词：

primary membranous nephropathy (PMN); rituximab (RTX); anti- (aPLA2R); anti-PLA2R antibody (aPLA2R); REMISSION; THERAPY; PHARMACOKINETICS; CYCLOPHOSPHAMIDE; COMBINATION; LIKELIHOOD; CELLS;

D O I：

10.5414/CN111228

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Rituximab (RTX) is the antiCD20 monoclonal antibody that has been used as the first-line therapy for primary membranous nephropathy (PMN) in recent years. However, the optimal dosing regimen and timing of RTX, or combination with other immunosuppressants, especially in patients with extremely high titers (> 1,000 RU/mL) of anti-PLA2R antibody (aPLA2R), are unclear at present. This report describes the case of a 70-year-old PMN patient with extremely high aPLA2R titer who failed to respond to very high doses of RTX. We also discuss the possible reasons for treatment failure.

引用

页码：63 / 68

页数：6

共 50 条

[1] Anti-phospholipase A2 receptor antibodies in membranous nephropathy
Lee, Sangho
KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) : 181 - 182
[2] Anti-Phospholipase A2 Receptor Antibodies and the Pathogenesis of Membranous Nephropathy
Ronco, Pierre
Debiec, Hanna
NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 232 - 237
[3] Anti-Phospholipase A2 Receptor Antibodies in Recurrent Membranous Nephropathy
Kattah, A.
Ayalon, R.
Beck, L. H., Jr.
Sethi, S.
Sandor, D. G.
Cosio, F. G.
Gandhi, M. J.
Lorenz, E. C.
Salant, D. J.
Fervenza, F. C.
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (05) : 1349 - 1359
[4] Anti-Phospholipase A2 Receptor Antibodies and Malignancy in Membranous Nephropathy
Timmermans, Sjoerd A. M. E. G.
Ayalon, Rivka
van Paassen, Pieter
Beck, Laurence H., Jr.
van Rie, Henk
Wirtz, Joris J. J. M.
Verseput, Gaico H.
Frenken, Leon A.
Salant, David J.
Tervaert, Jan Willem Cohen
AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (06) : 1223 - 1225
[5] Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
Ruggenenti, Piero
Debiec, Hanna
Ruggiero, Barbara
Chianca, Antonietta
Pelle, Timothee
Gaspari, Flavio
Suardi, Flavio
Gagliardini, Elena
Orisio, Silvia
Benigni, Ariela
Ronco, Pierre
Remuzzi, Giuseppe
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (10): : 2545 - 2558
[6] Hypercoagulability and dyslipidemia in membranous nephropathy with anti-phospholipase A2 receptor antibodies
Kitlinski, Michael
Heleniak, Zbigniew
Debska-Slizien, Alicja
RENAL FAILURE, 2025, 47 (01)
[7] ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES IN THE DIAGNOSIS OF IDIOPATHIC MEMBRANOUS NEPHROPATHY
Meneses, Guida
Viana, Helena
Santos, Maria Ceu
Ferreira, Carina
Calado, Joaquim
Carvalho, Fernanda
Remedio, Francisco
Nolasco, Fernando
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 198 - 198
[8] Anti-Phospholipase A2 Receptor Antibody in Membranous Nephropathy
Qin, Weisong
Beck, Laurence H., Jr.
Zeng, Caihong
Chen, Zhaohong
Li, Shijun
Zuo, Ke
Salant, David J.
Liu, Zhihong
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (06): : 1137 - 1143
[9] Anti-phospholipase A2 receptor antibodies in primary membranous nephropathy-10 key points
McQuarrie, Emily P.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (02) : 212 - 213
[10] Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy
Akiyama, Shin'ichi
Akiyama, Mari
Imai, Enyu
Ozaki, Takenori
Matsuo, Seiichi
Maruyama, Shoichi
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (04) : 653 - 660

← 1 2 3 4 5 →